Lilly Puts Down $200m To Use Dicerna's RNAi Platform For Metabolic, Neurological Diseases
Executive Summary
Dicerna CEO tells Scrip the companies talked for two years and the collaboration came together as new Lilly R&D leadership looked to add novel approaches. Milestone fees of $350m per target for 10 or more targets value the deal at $3.7bn.
You may also be interested in...
Lilly Supports RNA R&D Push With $700m Investment In Institute For Genetic Medicine
The big pharma has a gene therapy R&D site in New York from its Prevail Therapeutics buy; the RNA-focused Boston site also will conduct drug delivery research benefitting programs at both locations.
Big Pharma Deal Hunters Target RNA Approaches In Race To Build Best Platforms
The potential for RNA medicines to achieve holy grail goals – reaching undruggable targets and bringing drugs to market faster – has Pfizer, Lilly, Novartis and others in a deal-making frame of mind.
Roche Secures Dicerna RNAi Deal For Hepatitis B
Roche has paid $200m up front to get its hands on Dicerna’s RNAi-based drug for chronic hepatitis B in a deal that could be worth around $1.5bn.